Markers of Atherosclerosis. Part 1, Serological Markers

J 2019

Markers of Atherosclerosis. Part 1, Serological Markers

TIBAUT, Miha, Martin CAPRNDA, Peter KUBATKA, Andreja SINKOVIC, Vanda VALENTOVA et. al.

Basic information

Original name

Markers of Atherosclerosis. Part 1, Serological Markers

Authors

TIBAUT, Miha (705 Slovenia), Martin CAPRNDA (703 Slovakia), Peter KUBATKA (703 Slovakia), Andreja SINKOVIC (705 Slovenia), Vanda VALENTOVA (703 Slovakia), Slavomira FILIPOVA (703 Slovakia), Katarina GAZDIKOVA (703 Slovakia), Ludovit GASPAR (703 Slovakia), Ioana MOZOS (642 Romania), Emmanuel E. EGOM (124 Canada), Luis RODRIGO (724 Spain), Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and Daniel PETROVIC (705 Slovenia)

Edition

HEART LUNG AND CIRCULATION, NEW YORK, ELSEVIER SCIENCE INC, 2019, 1443-9506

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.194

RIV identification code

RIV/00216224:14110/19:00108495

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.hlc.2018.06.1057

UT WoS

000462780100007

Keywords in English

Biomarkers; Atherosderosis; High sensitivity C-reactive protein

Abstract

V originále

Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.

Links

NV17-29701A, research and development project

Name: Ischémií modifikovaný albumin a cirkulující mikroRNA jako nové technologie k monitorování tkáňové ischémie po cévních rekonstrukcích na břišní aortě

Citovat

TIBAUT, Miha, Martin CAPRNDA, Peter KUBATKA, Andreja SINKOVIC, Vanda VALENTOVA, Slavomira FILIPOVA, Katarina GAZDIKOVA, Ludovit GASPAR, Ioana MOZOS, Emmanuel E. EGOM, Luis RODRIGO, Peter KRUŽLIAK and Daniel PETROVIC. Markers of Atherosclerosis. Part 1, Serological Markers. HEART LUNG AND CIRCULATION. NEW YORK: ELSEVIER SCIENCE INC, 2019, vol. 28, No 5, p. 667-677. ISSN 1443-9506. Available from: https://dx.doi.org/10.1016/j.hlc.2018.06.1057.

@article{1545971,
   author = {Tibaut, Miha and Caprnda, Martin and Kubatka, Peter and Sinkovic, Andreja and Valentova, Vanda and Filipova, Slavomira and Gazdikova, Katarina and Gaspar, Ludovit and Mozos, Ioana and Egom, Emmanuel E. and Rodrigo, Luis and Kružliak, Peter and Petrovic, Daniel},
   article_location = {NEW YORK},
   article_number = {5},
   doi = {http://dx.doi.org/10.1016/j.hlc.2018.06.1057},
   keywords = {Biomarkers; Atherosderosis; High sensitivity C-reactive protein},
   language = {eng},
   issn = {1443-9506},
   journal = {HEART LUNG AND CIRCULATION},
   title = {Markers of Atherosclerosis. Part 1, Serological Markers},
   url = {http://dx.doi.org/10.1016/j.hlc.2018.06.1057},
   volume = {28},
   year = {2019}
}

TY  - JOUR
ID  - 1545971
AU  - Tibaut, Miha - Caprnda, Martin - Kubatka, Peter - Sinkovic, Andreja - Valentova, Vanda - Filipova, Slavomira - Gazdikova, Katarina - Gaspar, Ludovit - Mozos, Ioana - Egom, Emmanuel E. - Rodrigo, Luis - Kružliak, Peter - Petrovic, Daniel
PY  - 2019
TI  - Markers of Atherosclerosis. Part 1, Serological Markers
JF  - HEART LUNG AND CIRCULATION
VL  - 28
IS  - 5
SP  - 667-677
EP  - 667-677
PB  - ELSEVIER SCIENCE INC
SN  - 14439506
KW  - Biomarkers
KW  - Atherosderosis
KW  - High sensitivity C-reactive protein
UR  - http://dx.doi.org/10.1016/j.hlc.2018.06.1057
L2  - http://dx.doi.org/10.1016/j.hlc.2018.06.1057
N2  - Atherosclerosis is a major contributor to morbidity and mortality worldwide. With therapeutic consequences in mind, several risk scores are being used to differentiate individuals with low, intermediate or high cardiovascular (CV) event risk. The most appropriate management of intermediate risk individuals is still not known, therefore, novel biomarkers are being sought to help re-stratify them as low or high risk. This narrative review is presented in two parts. Here, in Part 1, we summarise current knowledge on serum (serological) biomarkers of atherosclerosis. Among novel biomarkers, high sensitivity C-reactive protein (hsCRP) has emerged as the most promising in chronic situations, others need further clinical studies. However, it seems that a combination of serum biomarkers offers more to risk stratification than either biomarker alone. In Part 2, we address genetic and imaging markers of atherosclerosis, as well as other developments relevant to risk prediction.
ER  -

TIBAUT, Miha, Martin CAPRNDA, Peter KUBATKA, Andreja SINKOVIC, Vanda VALENTOVA, Slavomira FILIPOVA, Katarina GAZDIKOVA, Ludovit GASPAR, Ioana MOZOS, Emmanuel E. EGOM, Luis RODRIGO, Peter KRUŽLIAK and Daniel PETROVIC. Markers of Atherosclerosis. Part 1, Serological Markers. \textit{HEART LUNG AND CIRCULATION}. NEW YORK: ELSEVIER SCIENCE INC, 2019, vol.~28, No~5, p.~667-677. ISSN~1443-9506. Available from: https://dx.doi.org/10.1016/j.hlc.2018.06.1057.

Detailed Information on Publication Record